Relevance of animal models to human tardive dyskinesia

Behavioral and Brain Functions

Volumn 8, Issue , 2012, Pages

  Blanchet, Pierre J ^a,b,c   Parent, Marie Thérèse ^a   Rompré, Pierre H ^a   Lévesque, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Antipsychotic drugs; Dopamine receptors; Non human primates; Stereotypies; Tardive dyskinesia; Vacuous chewing movements

Indexed keywords

4 (4 CHLOROPHENYL) 1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 1,2,3,6 TETRAHYDROPYRIDINE; APOMORPHINE; CHLORPROMAZINE; CHOLINE ACETYLTRANSFERASE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; FLUPHENAZINE; FLUPHENAZINE DECANOATE; GLUTAMATE DECARBOXYLASE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVODOPA; NUCLEAR RECEPTOR NUR77; OXIDOPAMINE; RESERPINE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT;

ADAPTIVE BEHAVIOR; ANIMAL MODEL; BABOON; CALLITRICHINAE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; DYSTONIA; FOLLOW UP; GLUCOSE METABOLISM; GUINEA PIG; HAPLORHINI; HUMAN; KNOCKOUT MOUSE; MACACA; MASTICATION; MOTOR DYSFUNCTION; MOUSE; MOUTH; MOVEMENT (PHYSIOLOGY); NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; RAT; REVIEW; SCHIZOPHRENIA; SCIURIDAE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STEREOTYPY; STRAIN DIFFERENCE; TARDIVE DYSKINESIA; TRANSGENIC MOUSE; TREATMENT DURATION; TREMOR; UPREGULATION; ANIMAL; DISEASE MODEL; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MOVEMENT DISORDERS; PRIMATES; RATS;

EID: 84857987306     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-8-12     Document Type: Review

References (92)

1. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003, 30(Suppl 1):S101-107.
2. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002, 181:422-427. 10.1192/bjp.181.5.422, 12411269.
3. Marshall DL, Hazlet TK, Gardner JS, Blough DK. Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study. J Man Care Pharm 2002, 8:259-265.
4. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010, 71:463-474. 10.4088/JCP.07m03890yel, 3109728, 20156410.
5. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shulman KI, Stukel T, Normand SL, Rochon PA. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005, 53:1374-1379. 10.1111/j.1532-5415.2005.53418.x, 16078964.
6. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2007, 257:169-172. 10.1007/s00406-006-0705-z, 17149539.
7. Blanchet PJ, Calon F, Morissette M, Hadj Tahar A, Bélanger N, Samadi P, Grondin R, Grégoire L, Meltzer L, Di Paolo T, Bédard PJ. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Rel Disord 2004, 10:297-304.
8. Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Rel Disord 2009, (15S):S18-S23.
9. Klawans HL, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972, 33:235-246. 10.1007/BF01245320, 4674512.
10. Waddington JL. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacol (Berl) 1990, 101:431-447.
11. Turrone P, Remington G, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy?. Neurosci Biobehav Rev 2002, 26:361-380. 10.1016/S0149-7634(02)00008-8, 12034136.
12. Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L. Haloperidol versus risperidone on rat "early onset" vacuous chewing. Behav Brain Res 2004, 149:9-16. 10.1016/S0166-4328(03)00192-X, 14739005.
13. Andreassen OA, Meshul CK, Moore C, Jorgensen HA. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Psychopharmacol (Berl) 2001, 157:11-19.
14. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jorgensen HA. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 2003, 122:717-725. 10.1016/j.neuroscience.2003.08.058, 14622915.
15. Meshul CK, Andreassen OA, Allen C, Jorgensen HA. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacol (Berl) 1996, 125:238-247.
16. Meredith GE, De Souza IE, Hyde TM, Tipper G, Wong ML, Egan MF. Persistent alterations in dendrites, spines, and dynorphinergic synapses in the nucleus accumbens shell of rats with neuroleptic-induced dyskinesias. J Neurosci 2000, 20:7798-7806.
17. Kelley JJ, Gao XM, Tamminga CA, Roberts RC. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Exp Neurol 1997, 146:471-478. 10.1006/exnr.1997.6552, 9270058.
18. Roberts RC, Lapidus B. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rats: a study of unlabeled and enkephalin-labeled striatal terminals. J Neural Transm 2003, 110:961-975. 10.1007/s00702-003-0013-y, 12938022.
19. Ellison G, See RE. Rats administered chronic neuroleptics develop oral movements which are similar in form to those in humans with tardive dyskinesia. Psychopharmacol (Berl) 1989, 98:564-566.
20. De Souza IEJ, Dawson NM, Clifford JJ, Waddington JL, Meredith GE. Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal. Psychopharmacol 2003, 169:28-34.
21. Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacol (Berl) 1996, 127:337-345.
22. Clow A, Theodorou A, Jenner P, Marsden CD. Cerebral dopamine function in rats following withdrawal from one year of continuous neuroleptic administration. Eur J Pharmacol 1980, 63:145-157. 10.1016/0014-2999(80)90438-0, 6103814.
23. Waddington JL, Cross AJ, Gamble SJ, Bourne RC. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 1983, 220:530-532. 10.1126/science.6132447, 6132447.
24. Turrone P, Remington G, Kapur S, Nobrega JN. Differential effects of within-day continuous vs transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacol 2003, 28:1433-1439.
25. Turrone P, Remington G, Kapur S, Nobrega JN. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry 2005, 57:406-411. 10.1016/j.biopsych.2004.10.023, 15705357.
26. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008, 64:145-152. 10.1016/j.biopsych.2008.01.010, 18295747.
27. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11 C]-raclopride PET study in cats. Neuropsychopharmacol 2009, 34:662-671.
28. Bédard AM, Maheux J, Lévesque D, Samaha AN. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacol 2011, 36:1248-1259.
29. Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran-Johnson TK, Jeste DV. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacol Bull 1992, 28:87-92.
30. Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacol 1993, 8:233-239.
31. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995, 52:756-765. 10.1001/archpsyc.1995.03950210050010, 7654127.
32. Bergamo M, Abilio VC, Queiroz CM, Barbosa-Junior HN, Abdanur LR, Frussa-Filho R. Effects of age on a new animal model of tardive dyskinesia. Neurobiol Aging 1997, 18:623-629. 10.1016/S0197-4580(97)00152-8, 9461060.
33. Steinpreis RE, Parret F, Summ RM, Panos JJ. Effects of clozapine and haloperidol on baseline levels of vacuous jaw movements in aged rats. Behav Brain Res 1997, 86:165-169. 10.1016/S0166-4328(96)02262-0, 9134151.
34. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacol (Berl) 1990, 102:474-478.
35. Silva RH, Abílio VC, Torres-Leite D, Bergamo M, Chinen CC, Claro FT, de Cássia Carvalho R, Frussa-Filho R. Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 2002, 132:171-177. 10.1016/S0166-4328(01)00409-0, 11997147.
36. Sumiyoshi T, Ichikawa J, Meltzer HY. Increased S(-)-apomorphine-induced vacuous chewing and attenuated effect of chronic haloperidol treatment in streptozotocin-induced diabetic rat. Pharmacol Biochem Behav 1997, 57:19-22. 10.1016/S0091-3057(96)00126-8, 9164549.
37. Glassman RB, Glassman HN. Oral dyskinesia in brain-damaged rats withdrawn from a neuroleptic: implications for models of tardive dyskinesia. Psychopharmacol (Berl) 1980, 69:19-25.
38. Kostrzewa RM, Huang N-Y, Kostrzewa JP, Nowak P, Brus R. Modeling tardive dyskinesia: predictive 5-HT2 receptor antagonist treatment. Neurotox Res 2007, 11:41-50. 10.1007/BF03033481, 17449447.
39. Neisewander JL, Castañeda E, Davis DA. Dose-dependent differences in the development of reserpine-induced oral dyskinesias in rats: support for a model of tardive dyskinesia. Psychopharmacol (Berl) 1994, 116:79-84.
40. Van Kampen JM, Stoessl AJ. Dopamine D1A receptor function in a rodent model of tardive dyskinesia. Neuroscience 2000, 101:629-635. 10.1016/S0306-4522(00)00412-7, 11113312.
41. Fibiger HC, Lloyd KG. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984, 7:462-464.
42. Waddington JL. Further anomalies in the dopamine receptor supersensitivity hypothesis of tardive dyskinesia. Trends Neurosci 1985, 8:200.
43. Andersson U, Eckernas SA, Hartvig P, Ulin J, Langstrom B, Häggström JE. Striatal binding of 11 C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J Neural Transm Gen Sect 1990, 79:215-226. 10.1007/BF01245132, 2137000.
44. Pedata F, Sorbi S, Pepeu G. Choline high-affinity uptake and metabolism and choline acetyltransferase activity in the striatum of rats chronically treated with neuroleptics. J Neurochem 1980, 35:606-611. 10.1111/j.1471-4159.1980.tb03698.x, 6108997.
45. Mahadik SP, Laev H, Korenovsky A, Karpiak SE. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol Psychiatry 1988, 24:199-217. 10.1016/0006-3223(88)90275-2, 3291956.
46. Jeste DV, Lohr JB, Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacol 1992, 106:154-160.
47. Carta AR, Gerfen CR. Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice. Neuroscience 1999, 90:1021-1029. 10.1016/S0306-4522(98)00498-9, 10218801.
48. Robertson GS, Lee CJ, Sridhar K, Nakabeppu Y, Cheng M, Wang YM, Caron MG. Clozapine-, but not haloperidol-, induced increases in ΔFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 2004, 20:3189-3194. 10.1111/j.1460-9568.2004.03774.x, 15579174.
49. Ethier I, Kagechika H, Shudo K, Rouillard C, Lévesque D. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry 2004, 56:522-526. 10.1016/j.biopsych.2004.06.036, 15450789.
50. Beaudry G, Langlois M-C, Weppe I, Rouillard C, Lévesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J Neurochem 2000, 75:1694-1702.
51. Langlois M-C, Beaudry G, Zekki H, Rouillard C, Lévesque D. Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience 2001, 106:117-128. 10.1016/S0306-4522(01)00248-2, 11564422.
52. Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, Le Foll B. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr Genet 2010, 20:39-43. 10.1097/YPG.0b013e3283351221, 20010315.
53. Paulson GW. Dyskinesias in monkeys. In Advances in Neurology 1973, 1:647-650. New York: Raven, Barbeau A, Chase TN, Paulson GW.
54. Gunne L-M, Bárány S. Haloperidol-induced tardive dyskinesias in monkeys. Psychopharmacol (Berl) 1976, 50:237-240.
55. Gunne L-M, Bárány S. A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacol (Berl) 1979, 63:195-198.
56. Bédard P, De Lean J, Lafleur J, Larochelle L. Haloperidol-induced dyskinesias in the monkey. Can J Neurol Sci 1977, 4:197-201.
57. Casey D. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin N Amer 1993, 16:689-710.
58. Halliday GM, Pond SM, Cartwright H, McRitchie DA, Castagnoli N, Van der Schyf CJ. Clinical and neuropathological abnormalities in baboons treated with HPTP, the tetrahydropyridine analog of haloperidol. Exp Neurol 1999, 158:155-163. 10.1006/exnr.1999.7090, 10448427.
59. Werge T, Elbaek Z, Andersen MB, Lundbaek JA, Rasmussen HB. Cebus apell, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans. The Pharmacogenomics J 2003, 3:97-100.
60. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997, 2:139-145. 10.1038/sj.mp.4000249, 9106238.
61. Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K. Tardive dyskinesia and ethnicity: review of the literature. Ann Clin Psychiatry 1997, 9:53-59.
62. Klintenberg R, Gunne L, Andrén PE. Tardive dyskinesia model in the common marmoset. Mov Disord 2002, 17:360-365. 10.1002/mds.10070, 11921124.
63. Jackson MJ, Al-Barghouthy G, Pearce RKB, Smith L, Hagan JJ, Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol Biochem Behav 2004, 79:391-400. 10.1016/j.pbb.2004.07.015, 15582011.
64. Lifshitz K, O'Keeffe RT, Lee KL, Linn GS, Mase D, Avery J, Lo ES, Cooper TB. Effect of extended depot fluphenazine treatment and withdrawal on social and other behaviors of Cebus apell monkeys. Psychopharmacol (Berl) 1991, 105:492-500.
65. Domino EF. Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review. In Dyskinesia - Research and Treatment (Psychopharmacology Supplementum 2) 1985, 217-223. Berlin Heidelberg: Springer, Casey DE, Chase TN, Christensen AV, Gerlach J.
66. Baca-Garcia E, Stanilla JK, Büchel C, Gattaz WF, de Leon J. Diurnal variability of orofacial dyskinetic movements. Pharmacopsychiat 1999, 32:73-75.
67. Gunne LM, Häggström JE, Johansson P, Levin ED, Terenius L. Neurobiochemical changes in tardive dyskinesia. L'Encéphale 1988, (XIV):167-173.
68. Stafford JEH, Jackson LS, Forrest TJ, Barrow A, Palmer RF. Haloperidol pharmacokinetics: a preliminary study in rhesus monkeys using a new radioimmunoassay procedure. J Pharmacol Methods 1981, 6:261-279. 10.1016/0160-5402(81)90067-X, 7334810.
69. Casey DE. Behavioral effects of long-term neuroleptic treatment in Cebus monkeys. In Dyskinesia - Research and Treatment (Psychopharmacology Supplementum 2) 1985, 211-216. Berlin Heidelberg: Springer, Casey DE, Chase TN, Christensen AV, Gerlach J.
70. Bédard PJ, Boucher R. Estradiol can suppress haloperidol-induced supersensitivity in dyskinetic monkeys. Neurosci Lett 1986, 64:206-210. 10.1016/0304-3940(86)90101-1, 3960400.
71. Van Hartesveldt C, Joyce JN. Effects of estrogen on the basal ganglia. Neurosci Biobehav Rev 1986, 10:1-14. 10.1016/0149-7634(86)90029-1, 2871534.
72. Fields JZ, Gordon JH. Permanent haloperidol-induced dopamine receptor up-regulation in the ovariectomized rat. Brain Res Bull 1991, 26:549-552. 10.1016/0361-9230(91)90094-Z, 1831063.
73. Bossé R, Di Paolo T. The modulation of brain dopamine and GABA-A receptors by estradiol: a clue for CNS changes occurring at menopause. Cell Mol Neurobiol 1996, 16:199-212. 10.1007/BF02088176, 8743969.
74. Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bédard PJ, Di Paolo T. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA-A receptors in the striatopallidal complex. Brain Res 1995, 680:43-52. 10.1016/0006-8993(95)00229-J, 7663983.
75. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992, 18:701-715.
76. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992, 89:4270-4274. 10.1073/pnas.89.10.4270, 49063, 1374894.
77. Simpson CS, Morris BJ. Haloperidol and fluphenazine induce junB gene expression in rat striatum and nucleus accumbens. J Neurochem 1994, 63:1955-1961.
78. Boegman RJ, Vincent SR. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 1996, 22:70-77. 10.1002/(SICI)1098-2396(199601)22:1<70::AID-SYN8>3.0.CO;2-F, 8822480.
79. Wirtshafter D, Asin KE. Effects of haloperidol and clozapine on Fos expression in the primate striatum. NeuroReport 2003, 14:2429-2432. 10.1097/00001756-200312190-00028, 14663205.
80. Gunne L-M, Häggström J-E, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984, 309:347-349. 10.1038/309347a0, 6727989.
81. Gunne LM, Andrén PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993, 16:90-95. 10.1097/00002826-199302000-00012, 8093682.
82. Mitchell IJ, Crossman AR, Liminga U, Andren P, Gunne LM. Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey. Mov Disord 1992, 7:32-37.
83. Deneau G, Crane GE. Dyskinesia in rhesus monkeys tested with high doses of chlorpromazine. A multidisciplinary workshop: Psychotropic drugs and dysfunctions of the basal ganglia 1969, 12-14. Washington: Public Health Service Publication No. 1938.
84. McKinney WT, Moran EC, Kraemer GW, Prange AJ. Long-term chlorpromazine in rhesus monkeys: production of dyskinesias and changes in social behavior. Psychopharmacol (Berl) 1980, 72:35-39.
85. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 1994, 91:4353-4356. 10.1073/pnas.91.10.4353, 43783, 8183912.
86. Lidow MS, Elsworth JD, Goldman-Rakic PS. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997, 281:597-603.
87. O'Connor JA, Hasenkamp W, Horman BM, Muly EC, Hemby SE. Region specific regulation of NR1 in rhesus monkeys following chronic antipsychotic drug administration. Biol Psychiatry 2006, 60:659-662. 10.1016/j.biopsych.2006.03.044, 16806093.
88. O'Connor JA, Muly EC, Arnold SE, Hemby SE. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs. Schizophr Res 2007, 90:28-40. 10.1016/j.schres.2006.10.004, 1868481, 17141476.
89. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacol 2005, 30:1649-1661.
90. Weiss B, Santelli S, Lusink G. Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacol (Berl) 1977, 53:289-293.
91. Bárány S, Ingvast A, Gunne L-M. Development of acute dystonia and tardive dyskinesia in Cebus monkeys. Res Commun Chem Pathol Pharmacol 1979, 25:269-279.
92. Kovacic B, Domino EF. A monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD. J Clin Psychopharmacol 1982, 2:305-307.